Gross profit for the third quarter 2024 was $147.6 million or 51.4% of revenue compared to $133.8 million or 48.6% of revenue year-over-year. The Company was able to offset price compression headwinds ...

Phase 1a dose escalation for CX-904 (EGFR-CD3 PROBODY® T-cell engager ... Risks and uncertainties that contribute to the ...

Expects to complete healthy volunteer Phase 1 clinical study of ATH-1105 by year end and begin dosing ALS patients in 2025 ...

A new focus on dermatology, ophthalmology, and gastroenterology will pave ways for many untapped opportunities that Viatris can utilize with its scale and manufacturing power. We believe Viatris is in ...

The trial's safety profile has been especially promising, with no dose-limiting toxicities observed and no discontinuations due to LP ... boost with the FDA granting Fast Track Designation in ...

And since back pain often rears its ugly head while you’re trying to drift off to sleep or ease yourself out of bed in the ...

LOTIS-5 full enrollment and LOTIS-7 initial efficacy, safety update anticipated by end of 2024 Updated ZYNLONTA® Phase 2 ...

Novozymes and Chr. Hansen have historically generated ample free cash flow and returned value to shareholders primarily through dividends. Management expects to continue to reward shareholders with a ...

Completed Enrollment of Dose Escalation Part of Phase 1 Clinical Trial of its Next-Generation Nectin-4 Targeting ADC (CRB-701) - First data ...

Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, today reported financial results for the ...

Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and ...

Ever heard of Moringa? Known in Nigeria as Sokale or okwe oyibo, these leaves pack so many health benefits. Click and discover: ...